Language Settings
Select Website Language

GDPR Compliance

We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

India Develops First Indigenous H5N1 Bird Flu Vaccine at ICAR-NIHSAD

1 day ago

10

0

India develops an indigenous H5N1 bird-flu vaccine for poultry, with doses reportedly costing ₹1–2 and a new animal disease research laboratory announced.

By News National Editorial Team

India has taken a significant step in strengthening its animal-health research capabilities with the development of an indigenous vaccine against H5N1 avian influenza, commonly known as bird flu. Scientists at the ICAR–National Institute of High Security Animal Diseases (ICAR-NIHSAD), based in Bhopal, developed the vaccine, according to reports published on November 20.

The development is important for India's poultry sector, which supports millions of livelihoods through farming, transportation, processing, retail and related industries. Outbreaks of highly pathogenic avian influenza can cause serious losses to poultry farmers and create challenges for animal-health authorities.

Vaccine designed for poultry protection

The reported vaccine price is approximately ₹1–2 per dose, potentially making it an affordable disease-prevention option for poultry operations. However, the actual cost of vaccination programmes can also include storage, transport, administration, monitoring and veterinary services.

H5N1 is a highly pathogenic avian influenza virus. It primarily affects birds, but certain strains can also infect humans following exposure to infected animals or contaminated environments. Public-health authorities therefore monitor outbreaks carefully.

The development of a locally produced vaccine could help India strengthen its preparedness and reduce dependence on imported animal-health products. It may also support research into other infectious diseases affecting livestock and poultry.

₹300-crore animal disease research facility announced

The November 20 report also highlighted a Centre announcement involving a ₹300-crore animal-disease research laboratory. Investment in specialised laboratories can improve diagnostic capacity, disease surveillance and scientific research.

Such facilities are particularly relevant to a country with a large livestock and poultry population. Faster identification of infectious diseases can help authorities respond earlier, investigate outbreaks and coordinate containment measures.

What poultry farmers should know

The vaccine announcement should not be interpreted as permission for farmers to begin vaccination without veterinary guidance. Its approved use, eligible poultry populations, vaccination schedule, storage requirements and regulatory status need to be confirmed through official veterinary authorities.

Farmers should continue following biosecurity measures, including restricting unnecessary farm access, cleaning equipment, monitoring bird health and reporting unusual mortality to local veterinary departments.

Why the development matters

India's poultry industry needs affordable disease-control tools, reliable veterinary infrastructure and strong surveillance systems. A domestic H5N1 vaccine could become an important part of that effort if regulatory approval and field effectiveness are established.

The next important steps will include transparent information about vaccine approval, field deployment and monitoring outcomes.

Sources:The Indian Express,Indian Express, November 20, 2026.

Click here to Read More
Previous Article
India's Electronics Exports Rise 44% to $31.97 Billion in FY2027
Next Article
India Arrests Six in International Drug Network Investigation Linked to US Shipments

Related India Updates:

Are you sure? You want to delete this comment..! Remove Cancel

Comments (0)

    Leave a comment